. Author manuscript; available in PMC: 2013 Jul 22.

Published in final edited form as: Clin Cancer Res. 2010 Nov 3;17(1):174–182. doi: 10.1158/1078-0432.CCR-10-1912

Table 2. Treatment Schema.

Mobilization and PBPC Procurement

Cyclophosphamide 1.5 gm/m² and G-CSF 10 microgram/kg/day to procure ≥ 4 × 10⁶ CD34+ cells/kg

Cycle 1

Melphalan 100 mg/m²/day × 2 days, then PBPC reinfusion and G-CSF 5 microgram/day starting day 5

Cycle 2

TMI followed by PBCS and G-CSF microgram/kg/day starting on day 0

Day -5	Day -4	Day -3	Day -2	Day -1	TMI dose level # of patients
cGy time					cGy		treated

200 am	200	200	200	200	1000	1	3

200 am	200	200	200	200	1200	2	4^*
200 pm	200	200	200	200	1200	2	4^*

200 am	200	200	200	200	1400	3	3
200 pm	200	200	200	200	1400	3	3

200 am	200	200	200	200	1600	4	6
200 pm	200	200	200	200	1600	4	6

200 am	200	200	200	200	1800	5	6
200 pm	200	200	200	200	1800	5	6

200 am	200	200	200		1600 cGy MTD Phase II dose
200 pm	200	200	200		1600 cGy MTD Phase II dose

Due to an unplanned downtime, one patient received only 1200 cGy.

Maintenance: Dexamethasone (40 mg/d × 4 days every 28 days) and thalidomide (50-200 mg/d)